Avid Bioservices Inc (CDMO)

[biopharm]

JBainseky, great question! Dmitry Gabrilovich has answsers... and I have been wondering about that slide from the very beginning, in combination with slide #38 of 45.

CJ's post of Dr. Brekkens slides:

investorshub.advfn.com/boards/read_msg.aspx?message_id=99937160

--------------------------------------------

I've written many posts in the past re: Notch Signaling and "all" complexities within this pathway takes on a chain reaction so to speak and PS targeting I say is what they are seeing that is initiating all these chain reactions "for the better" in many indications.

I'll make a bold claim right now, after looking through probably a hundred publications that mention IFNy (Interferon Gamma) and its relation to diabetes. I'll toss out a couple of the links below and have no time now but will try to organize a bunch of them that "may" show this is what Peregrine and KOL's are working towards re: progress in auto-immune diseases...

Ok... the above quote comes from that original long A$$ post and will continue off of that one to concentrate on Dmitry Gabrilovich MDSC's / Interferon-Gamme (slide 38 of 45) to show how we are moving towards many auto-immune diseases such as diabetes that PS targeting will be part of:

Myeloid Derived Suppressor Cells: Subsets,
Expansion, and Role in Cancer Progression ( IF you want other sources related to MDSC's, read this... at least the "intro" and the "conclusion" .... Its sooo damn obvious that researchers have been bewildered for years in what influences MDSC's !! Dmitry Gabrilovich knows clearly after Dr. Rolf Brekken took him on a tour of Bavi and PS targeting. If you decide to read the entire article... talks directly on MDSC's and lung cancer and melanoma as well.

http://cdn.intechopen.com/pdfs-wm/34381.pdf

..... Now, moving towards diabetes and its relation to MDSC's / IFN-Gamma..etc

Diabetes and Metabolism

Yang,
J Diabetes Metab 2013, S12
dx.doi.org/10.4172/2155-6156.S12-004


Abstract

Autoimmune diabetes is caused by a destruction of pancreatic ß-cells by autoreactive immune response,
leading to insulin insufficiency/deficiency and hyperglycemia and fatal complications. This disease afflicts up to
10 million people worldwide. There is no cure for autoimmune diabetes. Insulin injection is the only supportive
medication, which always accompanies fatality. Apart from replacement therapy using insulin and/or ß-cells,
immune interventions hold the key to stopping this illness. Myeloid-derived suppressor cells have emerged as a new
regulator in harnessing immune response. In this review, we first up-dated the advances on etiology, development
and immune interventions of autoimmune diabetes. Next, we highlighted the origin, development, tolerogenic
mechanisms of myeloid-derived suppressor cells with an emphasis of the signaling pathways in their development
and action. Finally, we summarized and discussed the recent progress in exploring the potential and mechanism of
myeloid-derived suppressor cells in autoimmune diabetes. A novel vista on MDSC-based immune intervention with
AID development was also discussed.

http://omicsonline.org/myeloid-derived-suppressor-cells-in-autoimmune-diabetes-their-antidiabetic-potential-and-mechanism-2155-6156.S12-004.pdf

.... as promised, a short post--- though that first link has 27 pages to read... so get reading : ) Its not just about oncology and vaccines.... we're at the tip of the ice berg here with PS targeting...